Seminars in Hematology
Volume 45, Supplement 1 , Pages S16-S20, April 2008

Platelet Tissue Factor: How Did It Get There and Is It Important?

  • Nigel S. Key

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nigel S. Key, MB ChB FRCP, Harold R. Roberts Professor of Medicine, Director, Harold R Roberts Comprehensive Hemophilia Center, 932 Mary Ellen Jones Building, CB #7035, Chapel Hill, NC 27599.

Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC.

Recently, the presence of functionally active tissue factor (TF) in platelets has been reported by several groups. In this location, TF is postulated to play an important role in the propagation phase of thrombus formation. Although the existence of platelet TF still remains controversial to some extent, a review of the current literature proposes at least three distinct sources of “platelet-associated TF” in those laboratories that have reported its presence: (1) TF that is taken up in the form of circulating microparticles, usually derived from monocytes; (2) TF stored in the α-granules of platelets that may have been taken up and/or endogenously synthesized; and (3) TF that is synthesized and expressed on the plasma membrane of mature platelets. These pathways are not mutually exclusive, and the dominant mechanism may depend on the state of platelet activation and, possibly, on other host factors that differ in physiological hemostasis versus pathological thrombosis. This brief review will summarize the state-of-the-art understanding on the origins and possible role of platelet TF.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 STATEMENT OF CONFLICT OF INTEREST: Nigel Key has received research grants from Novo Nordisk, and has served on advisory boards for Novo Nordisk and Baxter.

PII: S0037-1963(08)00052-8

doi:10.1053/j.seminhematol.2008.03.012

Seminars in Hematology
Volume 45, Supplement 1 , Pages S16-S20, April 2008